AR087471A1 - Metodos de tratamiento de enfermedades degenerativas de la retina - Google Patents
Metodos de tratamiento de enfermedades degenerativas de la retinaInfo
- Publication number
- AR087471A1 AR087471A1 ARP120102872A ARP120102872A AR087471A1 AR 087471 A1 AR087471 A1 AR 087471A1 AR P120102872 A ARP120102872 A AR P120102872A AR P120102872 A ARP120102872 A AR P120102872A AR 087471 A1 AR087471 A1 AR 087471A1
- Authority
- AR
- Argentina
- Prior art keywords
- cell
- group
- wnt
- stem cell
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0623—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/415—Wnt; Frizzeled
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Developmental Biology & Embryology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Reivindicación 1: Una célula seleccionada del grupo que consiste en una célula madre hematopoyética (HSC), una célula progenitora, y una célula madre mesenquimal (MSC), en donde la ruta de señalización Wnt/b-catenina de dicha célula está activada, para su uso en el tratamiento de una enfermedad de degeneración retiniana.Reivindicación 5: Célula para su uso en el tratamiento de una enfermedad de degeneración retiniana según cualquiera de las reivindicaciones 1 a 4, en la que dicha enfermedad de degeneración retiniana se selecciona del grupo que consiste en retinitis pigmentosa, degeneración macular relacionada con la edad, enfermedad de Stargardt, distrofia de conos-bastones, ceguera nocturna estacionaria congénita, amaurosis congénita de Leber, distrofia macular viteliforme de Best, neuropatía óptica isquémica anterior, coroideremia, degeneración macular relacionada con la edad, distrofia foveomacular, distrofia corneoretiniana cristalina de Bietti, síndrome de Usher, y un estado degenerativo retiniano derivado de una patología primaria. Reivindicación 26: Una composición farmacéutica seleccionada del grupo que consiste en: 1) una composición farmacéutica que comprende al menos una célula seleccionada del grupo que consiste en una célula madre hematopoyética (HSC), una célula progenitora, una célula madre mesenquimal (MSC) y cualquier combinación de las mismas, en la que la ruta de señalización Wnt/b-catenina de dichas células está activada, y un portador farmacéuticamente aceptable, y 2) una composición farmacéutica que comprende al menos una célula seleccionada del grupo que consiste en una célula madre hematopoyética (HSC), una célula progenitora, una célula madre mesenquimal (MSC) y cualquier combinación de las mismas, en combinación con un activador de la ruta de señalización Wnt/b-catenina o un inhibidor de un represor de la ruta de señalización Wnt/b-catenina y un portador farmacéuticamente aceptable. Reivindicación 27: Un kit seleccionado del grupo que consiste en: 1) un kit que comprende al menos una célula seleccionada del grupo que consiste en una célula madre hematopoyética (HSC), una célula progenitora, una célula madre mesenquimal (MSC) y cualquier combinación de las mismas, en el que la ruta de señalización Wnt/b-catenina de dichas células está activada, e instrucciones para el uso de los componentes del kit, y 2) un kit que comprende al menos una célula seleccionada del grupo que consiste en una célula madre hematopoyética (HSC), una célula progenitora, una célula madre mesenquimal (MSC) y cualquier combinación de las mismas, en combinación con un activador de la ruta de señalización Wnt/b-catenina o un inhibidor de un represor de la ruta de señalización Wnt/b-catenina, e instrucciones para el uso de los componentes del kit.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11176713A EP2554662A1 (en) | 2011-08-05 | 2011-08-05 | Methods of treatment of retinal degeneration diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR087471A1 true AR087471A1 (es) | 2014-03-26 |
Family
ID=46826437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120102872A AR087471A1 (es) | 2011-08-05 | 2012-08-06 | Metodos de tratamiento de enfermedades degenerativas de la retina |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20140199277A1 (es) |
| EP (2) | EP2554662A1 (es) |
| JP (1) | JP2014527407A (es) |
| KR (1) | KR20140068936A (es) |
| CN (1) | CN104011203A (es) |
| AR (1) | AR087471A1 (es) |
| AU (1) | AU2012293681A1 (es) |
| BR (1) | BR112014002718A8 (es) |
| CA (1) | CA2844106A1 (es) |
| CO (1) | CO7081142A2 (es) |
| IL (1) | IL230830A0 (es) |
| MX (1) | MX2014001475A (es) |
| RU (1) | RU2014108478A (es) |
| SG (1) | SG2014008080A (es) |
| WO (1) | WO2013020945A1 (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013045694A1 (en) | 2011-09-29 | 2013-04-04 | The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Compositions and methods for the treatment of degenerative retinal conditions |
| CA2937129A1 (en) | 2014-01-17 | 2015-07-23 | Sumitomo Chemical Company, Limited | Method for manufacturing ciliary margin stem cells |
| RU2718047C2 (ru) * | 2014-09-16 | 2020-03-30 | Джензим Корпорейшн | Аденоассоциированные вирусные векторы для лечения миоцилиновой (myoc) глаукомы |
| RU2578526C1 (ru) * | 2014-12-25 | 2016-03-27 | федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации | Способ получения органной культуры хороидально-пигментного комплекса из глаза взрослого донора-трупа |
| RU2569481C1 (ru) * | 2014-12-25 | 2015-11-27 | федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации | Способ получения культуры клеток ретинального пигментного эпителия из глаза взрослого донора-трупа |
| KR101779932B1 (ko) * | 2015-09-15 | 2017-09-21 | 주식회사 스템랩 | 나노그(Nanog)를 도입한 양수 내 태아 유래 중간엽 줄기세포를 이용한 육모 촉진용 조성물의 제조방법 |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| KR101674622B1 (ko) * | 2016-07-07 | 2016-11-09 | 국민대학교산학협력단 | 세스퀴테르펜 유도체의 신규한 용도 |
| CA3032153A1 (en) * | 2016-08-19 | 2018-02-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selective estrogen-receptor modulators (serms) confer protection against photoreceptor degeneration |
| US11180537B2 (en) * | 2016-11-06 | 2021-11-23 | Nancoscope Technologies LLC | Optogenetic modulation by Multi-Characteristic Opsins for vision restoration and other applications |
| US10719936B2 (en) | 2017-04-27 | 2020-07-21 | Retinascan Limited | System and method for automated funduscopic image analysis |
| CA3063632A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Benzofurane and benzothiophene derivatives as pge2 receptor modulators |
| MA49128A (fr) | 2017-05-18 | 2021-03-17 | Idorsia Pharmaceuticals Ltd | Dérivés de pyrimidine utilisés en tant que modulateurs des récepteurs des pge2 |
| TW201900180A (zh) | 2017-05-18 | 2019-01-01 | 瑞士商愛杜西亞製藥有限公司 | 嘧啶衍生物 |
| PE20191787A1 (es) | 2017-05-18 | 2019-12-24 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituidos |
| ES2893452T3 (es) | 2017-05-18 | 2022-02-09 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de PGE2 |
| WO2018232258A1 (en) * | 2017-06-15 | 2018-12-20 | University Of North Texas Health Science Center | Reprogramming fibroblasts to retinal cells |
| CN117379543A (zh) * | 2017-08-20 | 2024-01-12 | 加州大学董事会 | 治疗青光眼的Wnt5a的调节 |
| WO2019195717A1 (en) * | 2018-04-06 | 2019-10-10 | Icahn School Of Medicine At Mount Sinai | Compositions and methods of treatment of vision loss through generation of rod photoreceptors from müller glial cells |
| EP3937955A4 (en) * | 2019-03-15 | 2022-12-07 | The Schepens Eye Research Institute, Inc. | ISOLATION, ENHANCEMENT AND EXPANSION OF CONICAL PROGENITOR CELLS AND THEIR USES |
| CN110706164A (zh) * | 2019-09-03 | 2020-01-17 | 北京爱博同心医学科技有限公司 | 基于增强现实的管状视野图像变形显示方法及眼镜 |
| US20230034053A1 (en) * | 2019-09-25 | 2023-02-02 | The Board Of Trustees Of The Leland Stanford Junior University | Metabolic rescue of retinal degeneration |
| KR20210119766A (ko) * | 2020-03-25 | 2021-10-06 | 서울대학교병원 | 인간 배아줄기세포 유래 중간엽 줄기세포를 포함하는 망막색소변성의 예방 또는 치료용 약학적 조성물 |
| KR102655748B1 (ko) * | 2023-06-08 | 2024-04-05 | 충북대학교 산학협력단 | 고포도당 조건에서의 중간엽 줄기세포의 생존율을 증가시키는 방법 |
| KR102655735B1 (ko) * | 2023-06-09 | 2024-04-05 | 충북대학교 산학협력단 | 당뇨성 망막병증의 예방 및 치료를 위한 타크로리무스 전처리 줄기세포 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6128654A (en) | 1997-02-14 | 2000-10-03 | Advanced Micro Devices, Inc. | Method and apparatus for transmitting multiple copies by replicating data identifiers |
| US7045519B2 (en) | 1998-06-19 | 2006-05-16 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
| US6417185B1 (en) | 1998-06-19 | 2002-07-09 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
| DE60037905T2 (de) | 1999-12-17 | 2009-01-29 | Novartis Vaccines and Diagnostics, Inc., Emeryville | Pyrazin-basierte hemmer der glycogen-synthase-kinase 3 |
| ATE303383T1 (de) | 1999-12-17 | 2005-09-15 | Chiron Corp | Bizyklische inhibitoren von glycogen synthase kinase 3 |
| KR100860827B1 (ko) | 2000-09-06 | 2008-09-30 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 글리코겐 합성효소 키나아제 3의 억제제 |
| EP1650203B1 (en) | 2000-09-11 | 2008-02-20 | Novartis Vaccines and Diagnostics, Inc. | Process of preparation of benzimidazol-2-yl quinolinone derivatives |
| DE60214703T2 (de) | 2001-06-01 | 2007-09-13 | Vertex Pharmaceuticals Inc., Cambridge | Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen |
| JP4656838B2 (ja) | 2002-02-06 | 2011-03-23 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｇｓｋ−３の阻害剤として有用なヘテロアリール化合物 |
| WO2003074072A1 (en) | 2002-03-01 | 2003-09-12 | Chiron Corporation | Methods and compositions for the treatment of ischemia |
| US7838290B2 (en) * | 2002-07-25 | 2010-11-23 | The Scripps Research Institute | Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith |
| US20050129665A1 (en) * | 2002-07-25 | 2005-06-16 | Martin Friedlander | Isolated lineage negative hematopoietic stem cells and methods of treatment therewith |
| CA2496246A1 (en) | 2002-08-23 | 2004-03-04 | Chiron Corporation | Pyrrole based inhibitors of glycogen synthase kinase 3 |
| CA2502819A1 (en) | 2002-10-21 | 2004-05-06 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
| BRPI0409861A (pt) * | 2003-05-02 | 2006-05-16 | Scripps Research Inst | células- tronco hematopoiéticas e sua utilização em métodos de tratamento de doenças oculares neovasculares |
| JP2007502300A (ja) | 2003-08-13 | 2007-02-08 | カイロン コーポレイション | Ｇｓｋ−３インヒビターおよびその使用 |
| MX2007002639A (es) * | 2004-09-03 | 2007-08-06 | Scripps Research Inst | Celulas madre hematopoyeticas de linaje negativo aisladas y metodos de tratamiento con las mismas. |
| US7850960B2 (en) * | 2004-12-30 | 2010-12-14 | University Of Washington | Methods for regulation of stem cells |
| US20070231306A1 (en) * | 2005-02-24 | 2007-10-04 | The Scripps Research Institute | Isolated myeloid-like cell populations and methods of treatment therewith |
| CA2599172A1 (en) | 2005-02-24 | 2006-08-31 | The Scripps Research Institute | Method for the treatment of retinopathy of prematurity and related retinopathic diseases |
| PL1888123T3 (pl) * | 2005-06-08 | 2013-06-28 | Janssen Biotech Inc | Terapia komórkowa chorób degeneracyjnych oka |
| AU2008266885A1 (en) * | 2007-06-15 | 2008-12-24 | Garnet Biotherapeutics Inc. | Treatment of diseases and disorders using self-renewing colony forming cells cultured and expanded in vitro |
| EP2090649A1 (en) | 2008-02-13 | 2009-08-19 | Fondazione Telethon | Method for reprogramming differentiated cells |
| GB0816577D0 (en) * | 2008-09-11 | 2008-10-15 | Axordia Ltd | Growth factor |
| CN102712900B (zh) * | 2009-10-06 | 2015-07-01 | 首尔大学校产学协力团 | 干细胞分化成为视网膜细胞的方法 |
-
2011
- 2011-08-05 EP EP11176713A patent/EP2554662A1/en not_active Withdrawn
-
2012
- 2012-08-06 BR BR112014002718A patent/BR112014002718A8/pt not_active IP Right Cessation
- 2012-08-06 WO PCT/EP2012/065327 patent/WO2013020945A1/en active Application Filing
- 2012-08-06 JP JP2014523346A patent/JP2014527407A/ja active Pending
- 2012-08-06 RU RU2014108478/10A patent/RU2014108478A/ru not_active Application Discontinuation
- 2012-08-06 CN CN201280049453.2A patent/CN104011203A/zh active Pending
- 2012-08-06 KR KR1020147006060A patent/KR20140068936A/ko not_active Application Discontinuation
- 2012-08-06 CA CA2844106A patent/CA2844106A1/en not_active Abandoned
- 2012-08-06 AU AU2012293681A patent/AU2012293681A1/en not_active Abandoned
- 2012-08-06 AR ARP120102872A patent/AR087471A1/es unknown
- 2012-08-06 SG SG2014008080A patent/SG2014008080A/en unknown
- 2012-08-06 EP EP12756386.4A patent/EP2739723A1/en not_active Withdrawn
- 2012-08-06 US US14/237,297 patent/US20140199277A1/en not_active Abandoned
- 2012-08-06 MX MX2014001475A patent/MX2014001475A/es not_active Application Discontinuation
-
2014
- 2014-02-05 IL IL230830A patent/IL230830A0/en unknown
- 2014-03-05 CO CO14047158A patent/CO7081142A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014002718A2 (pt) | 2017-06-13 |
| IL230830A0 (en) | 2014-03-31 |
| EP2554662A1 (en) | 2013-02-06 |
| JP2014527407A (ja) | 2014-10-16 |
| CO7081142A2 (es) | 2014-10-10 |
| KR20140068936A (ko) | 2014-06-09 |
| CN104011203A (zh) | 2014-08-27 |
| SG2014008080A (en) | 2014-03-28 |
| NZ621345A (en) | 2015-09-25 |
| EP2739723A1 (en) | 2014-06-11 |
| WO2013020945A1 (en) | 2013-02-14 |
| US20140199277A1 (en) | 2014-07-17 |
| BR112014002718A8 (pt) | 2017-06-20 |
| WO2013020945A9 (en) | 2013-04-04 |
| RU2014108478A (ru) | 2015-09-10 |
| MX2014001475A (es) | 2014-07-22 |
| AU2012293681A1 (en) | 2014-03-06 |
| CA2844106A1 (en) | 2013-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR087471A1 (es) | Metodos de tratamiento de enfermedades degenerativas de la retina | |
| CU20110096A7 (es) | Compuestos que expanden las células madre hematopoyéticas | |
| CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| BR112014018524A8 (pt) | Derivados de pirimido [4,5-b]indol, seus usos, composição farmaceutica, e método in vivo ou ex vivo para aumentar as células estaminais e/ou progenitoras | |
| UY37098A (es) | Moduladores de ror-gamma | |
| CL2016003293A1 (es) | Inhibidores de mnk y método relacionado al mismo | |
| PE20151090A1 (es) | Lactamas fusionadas de arilo y heteroarilo | |
| CL2020002698A1 (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos | |
| UY33183A (es) | Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento | |
| CL2014001158A1 (es) | Compuestos derivados de piperazina alquilados; composicion farmaceutica que los comprende; proceso para preparar la composicion farmaceutica; kit y uso en el tratamiento de trastornos inmunes, cancer, enfermedades cardiovasculares, inflamacion, entre otros. | |
| CO6670575A2 (es) | Aminopirazoloqinazolinas sustituidas, útiles en el tratamiento de enfermedades proliferativas y composiciones farmaceúticas que las continen | |
| JP2014527407A5 (es) | ||
| CL2015002546A1 (es) | Derivados 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftálmicos | |
| AR088382A1 (es) | Formulaciones de etanercept estabilizadas con xilitol | |
| CR20160528A (es) | Compuestos y composiciones para inducir condrogénesis | |
| CL2012002355A1 (es) | Compuestos derivados de 1,3,4,8-tetrahidro-2h-pirido[1,2-a]pirazina; composicion farmaceutica que los comprende; kit farmaceutico; y su uso como inhibidores de la integrasa del vih para el tratamiento de una enfermedad infecciosa del vih. | |
| AR098693A1 (es) | Método para producir células del epitelio pigmentario retiniano (rpe) | |
| CL2018000413A1 (es) | Composición y productos que comprenden células senescentes para su uso en la regeneración de tejidos | |
| CO2021006114A2 (es) | Derivados de 2,3-dihidro-1h-pirrolo[3,4-c]piridin-1-ona como inhibidores de hpk1 para el tratamiento del cáncer | |
| ECSP11011067A (es) | Compuestos para el tratamiento de enfermedades y desórdenes oftalmológicos | |
| ECSP16074478A (es) | Compuestos novedosos | |
| UY35293A (es) | Isotiazoles sustituidos con amino | |
| DOP2017000073A (es) | Nuevos activadores de la guanilato ciclasa soluble y su uso | |
| CO2017012994A2 (es) | Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa | |
| AR102779A1 (es) | Composición farmacéutica, su preparación y sus usos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |